IN2014DN07875A - - Google Patents

Info

Publication number
IN2014DN07875A
IN2014DN07875A IN7875DEN2014A IN2014DN07875A IN 2014DN07875 A IN2014DN07875 A IN 2014DN07875A IN 7875DEN2014 A IN7875DEN2014 A IN 7875DEN2014A IN 2014DN07875 A IN2014DN07875 A IN 2014DN07875A
Authority
IN
India
Prior art keywords
peptide
therapeutic agent
ssvlyggppsaa
histone
conjugate
Prior art date
Application number
Other languages
English (en)
Inventor
Shuji Sato
Takeshi Goto
Naoya Ohmori
Kueichen Chiang
Yayoi Shimada
Masafumi Inomata
Toru Kusano
Takahiro Hiratsuka
Takayuki Noguchi
Satoshi Hagiwara
Original Assignee
Josai University Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Josai University Corp filed Critical Josai University Corp
Publication of IN2014DN07875A publication Critical patent/IN2014DN07875A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IN7875DEN2014 2012-02-22 2013-02-22 IN2014DN07875A (th)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012035965A JP2015117181A (ja) 2012-02-22 2012-02-22 敗血症治療剤
PCT/JP2013/054551 WO2013125687A1 (ja) 2012-02-22 2013-02-22 炎症疾患治療剤

Publications (1)

Publication Number Publication Date
IN2014DN07875A true IN2014DN07875A (th) 2015-04-24

Family

ID=49005863

Family Applications (1)

Application Number Title Priority Date Filing Date
IN7875DEN2014 IN2014DN07875A (th) 2012-02-22 2013-02-22

Country Status (8)

Country Link
US (2) US20150079090A1 (th)
EP (1) EP2815763B1 (th)
JP (1) JP2015117181A (th)
KR (1) KR102159412B1 (th)
CN (1) CN104379165B (th)
IN (1) IN2014DN07875A (th)
TW (1) TWI605059B (th)
WO (1) WO2013125687A1 (th)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101863978B1 (ko) 2010-08-20 2018-06-01 각코우호우진 조사이 다이가쿠 면역 억제 활성을 갖는 모노클로날 항체 또는 그것의 항원 결합 단편
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
AU2017239637A1 (en) * 2016-03-29 2018-11-15 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
EP3511419A4 (en) * 2016-09-23 2020-06-24 TFK Co., Ltd COMPOUND OR SALT THEREOF, ANTI-INFLAMMATORY AGENT, ANTI-CANCER AGENT FOR LUNG CANCER, METHOD FOR PRODUCING THE COMPOUND OR SALT THEREOF, METHOD FOR TREATING INFLAMMATORY DISEASE, AND METHOD FOR TREATING LUNG CANCER

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4855261B2 (ja) * 2004-09-03 2012-01-18 アマテラスファーマ株式会社 抗ヒストンｈ１モノクローナル抗体およびこれを産生するハイブリドーマ
WO2009044555A1 (ja) * 2007-10-04 2009-04-09 Josai University Corporation 製剤、当該製剤を用いたワクチンの投与方法及びイオントフォレーシス装置
CA2704974C (en) * 2007-11-06 2019-06-04 Oklahoma Medical Research Foundation Extracellular histones as biomarkers for prognosis and molecular targets for therapy
KR101863978B1 (ko) * 2010-08-20 2018-06-01 각코우호우진 조사이 다이가쿠 면역 억제 활성을 갖는 모노클로날 항체 또는 그것의 항원 결합 단편

Also Published As

Publication number Publication date
CN104379165A (zh) 2015-02-25
TWI605059B (zh) 2017-11-11
TW201350502A (zh) 2013-12-16
EP2815763A1 (en) 2014-12-24
EP2815763B1 (en) 2018-06-13
WO2013125687A1 (ja) 2013-08-29
KR102159412B1 (ko) 2020-09-23
US20150079090A1 (en) 2015-03-19
JP2015117181A (ja) 2015-06-25
KR20140138699A (ko) 2014-12-04
EP2815763A4 (en) 2015-07-22
US20170096478A1 (en) 2017-04-06
CN104379165B (zh) 2018-08-03

Similar Documents

Publication Publication Date Title
NZ713461A (en) Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
MX353931B (es) Anticuerpos que se unen a ox40 y sus usos.
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
EP2532366A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
MX2014005108A (es) Constructos de polipeptidos y sus usos.
JO3625B1 (ar) بروتينات رابطة للأنتيجين cd27l
NZ610267A (en) A monoclonal antibody framework binding interface for meditopes, meditope delivery systems and methods for their use
NZ607969A (en) Cd33 binding agents
IN2014KN01715A (th)
PH12014501783B1 (en) Anti-lipoarabinomannan antibody and immunoassay for acid-fast bacillary infection using the antibody
EP2532365A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
UA111818C2 (uk) Антитіло проти csf-1r
AR096364A1 (es) Anticuerpos receptores de antitransferina y métodos de uso
NZ607710A (en) 4-1bb binding molecules
MX2014001375A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX357193B (es) Moleculas de union anti-alfa sinucleina.
MX340015B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
NZ630847A (en) Anti-sema4d antibodies and epitopes
SG178886A1 (en) Humanized anti-cdcp1 antibodies
UA113623C2 (uk) Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi)
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
EA201270701A1 (ru) Ингибирующие металлопротеины антитела
IN2014DN07875A (th)
IN2013MN00513A (th)